Saturday 17 October 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 2.67% and free cash flow grew 60.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

86.17 1.80 −2.05%

Follow RYTM

Alert me

Market cap: $6.1B
P/E: 0.0×
Fwd P/E: −26.9×
Dividend yield: —
F-score: 6/9
Altman Z: 15.89
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 38.64

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	—	3	1	—	1	1	—	5	1	—

Insider Ownership 3.59%

Capital & Financial Ratios $m

Market Cap 6,060.00

Revenue 239.92

Net Income (205.35)

Free Cash Flow (105.35)

Net Debt (330.90)

Current Ratio 3.45

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (26.90)

P/S ratio 24.64

P/B ratio 57.39

Past 5Y EPS Growth —

This Y EPS Growth 5.28%

Next Y EPS Growth 78.06%

Next Y revenue growth 66.05%

Next 5Y EPS Growth 32.06%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.40%

10-year low 10-year high

P/B against its own 10 years 84.62%

10-year low 10-year high

EV/Sales against its own 10 years 16.60%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	276	321	389	331
Receivables	15	19	26	40
Inventory	9	19	26	31
Other	—	—	—	—
	308	374	467	427

	2023	2024	2025	Q'26
Payables	5	12	14	16
ST’ Debt	—	—	—	—
Other	—	38	—	—
	55	116	106	124

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	100.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	23.77%	10.15%	0.72%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	60	71	—	—	—
’25	33	49	51	57	190
’24	26	29	33	42	130
’23	11	19	23	24	77
’22	1	9	4	9	24

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(9)	—	—	—
’25	(40)	(23)	(27)	(25)	(116)
’24	(41)	(29)	(25)	(19)	(114)
’23	(36)	(41)	(29)	(29)	(136)
’22	(54)	(39)	(47)	(34)	(173)
’21	(34)	(32)	(40)	(40)	(146)
’20	(36)	(30)	(27)	(29)	(122)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(9)	—	—	—
’25	(40)	(23)	(67)	(26)	(157)
’24	(81)	(29)	(26)	(19)	(154)
’23	(41)	(42)	(30)	(29)	(142)
’22	(54)	(43)	(47)	(34)	(178)
’21	(34)	(37)	(40)	(34)	(144)
’20	(36)	(30)	(27)	(29)	(122)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.83)	(0.73)	—	—	—
’25	(0.81)	(0.75)	(0.82)	(0.73)	(3.11)
’24	(2.35)	(0.55)	(0.73)	(0.72)	(4.34)
’23	(0.92)	(0.82)	(0.76)	(0.70)	(3.20)
’22	(1.05)	(0.89)	(0.79)	(0.75)	(3.47)
’21	0.90	(0.70)	(0.70)	(0.85)	(1.40)
’20	(0.78)	(0.71)	(0.77)	(0.79)	(3.04)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	21.38	16.80	18.00	12.99	8.44	3.04	15.50	35.17	45.91	Analyst estimates 2026–2028 Powerpack
	High	—	31.63	37.23	31.94	34.27	43.26	30.98	50.28	68.58	122.20
People
People	Employees	15	26	54	70	90	140	177	226	283	414
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.02	0.13	0.34	0.46	0.46
Income, $m
Income, $m	Revenue	—	—	—	—	—	3	24	77	130	190
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	81.01	90.98	87.99	89.73	89.73
	EBT	(26)	(34)	(74)	(141)	(134)	(70)	(181)	(184)	(260)	(196)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(2,207.10)	(766.22)	(237.79)	(200.00)	(103.31)
	Net income	(26)	(34)	(74)	(141)	(134)	(70)	(181)	(185)	(261)	(197)
	Depreciation	0	0	0	1	1	1	2	2	2	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.06	0.45	1.34	2.13	2.92
	Earnings	(2.54)	(2.83)	(2.39)	(3.86)	(3.04)	(1.40)	(3.47)	(3.20)	(4.34)	(3.11)
	Cash flow	(2.28)	(2.22)	(2.00)	(3.37)	(2.76)	(2.94)	(3.33)	(2.36)	(1.87)	(1.78)
	Capex	(0.10)	(0.01)	(0.02)	(0.09)	0.00	0.03	(0.08)	(0.10)	(0.66)	(0.63)
	Free cash flow	(2.38)	(2.23)	(2.02)	(3.46)	(2.77)	(2.91)	(3.41)	(2.46)	(2.53)	(2.41)
	Book value	0.72	10.91	7.94	7.72	3.77	5.73	5.07	2.94	2.70	4.16
	Shares, m	10	13	31	36	44	50	52	58	61	65
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	156.95	63.15	33.62	26.24	36.66
	P/B	—	—	—	—	—	1.74	5.65	15.33	157.14	50.02
	EV/Sales	—	—	—	—	—	63.46	49.05	30.05	23.78	34.61
	EV/FCF	—	—	—	—	—	(1.39)	(6.79)	(15.95)	(19.53)	(40.76)
Cash, $m
Cash, $m	Operating cash flow	(23)	(29)	(62)	(123)	(122)	(146)	(173)	(136)	(114)	(116)
	Capex	(1)	0	(1)	(3)	0	2	(4)	(6)	(40)	(41)
	Free cash flow	(24)	(30)	(63)	(126)	(122)	(144)	(178)	(142)	(154)	(157)
Balance, $m
Balance, $m	Working capital	6	144	245	278	164	265	314	253	259	361
	Total debt	—	—	—	4	3	3	78	—	—	—
	Net debt	(11)	(148)	(252)	(292)	(173)	(295)	(333)	(276)	(321)	(389)
	Shareholders’ equity	7	145	246	281	167	284	264	170	165	270
Returns, %
Returns, %	ROA	(117.20)	(45.81)	(35.96)	(49.49)	(54.07)	(26.95)	(50.88)	(51.64)	(72.98)	(46.29)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	142.86	(67.06)	(37.88)	(53.38)	(59.88)	(30.89)	(66.05)	(85.10)	(276.33)	(251.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PRAX Praxis Precision Medicines, Inc.	$6.9B	— (loss-making)	— (loss-making)	+1,349.13% (above 0%: growing)	n/m	−43.54% (below 0%: shrinking)	100.00%	0.00%	Compare
IOVA Iovance Biotherapeutics, Inc.	$6.7B	— (loss-making)	— (loss-making)	+65.65% (above 0%: growing)	n/m	+11.52% (above 0%: growing)	56.10%	(52.26%)	Compare
BLTE Belite Bio, Inc. Sponsored ADR	$6.2B	— (loss-making)	—	—	n/m	+64.67% (above 0%: growing)	—	0.00%	Compare
RYTM Rhythm Pharmaceuticals, Inc.	$6.1B	— (loss-making)	— (loss-making)	+46.91% (above 0%: growing)	n/m	+60.74% (above 0%: growing)	87.47%	(68.14%)
LGND Ligand Pharmaceuticals Incorporated	$6.0B	29.5×	54.7×	+33.73% (above 0%: growing)	+868.00% (above 0%: growing)	+35.53% (above 0%: growing)	94.95%	13.49%	Compare
IMVT Immunovant, Inc.	$5.7B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
KOD Kodiak Sciences Inc.	$5.5B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
Median of peers	$5.8B	—	—	+65.65%	—	−19.91%	56.10%	0.00%

All 614 Biotechnology stocks →

Rhythm Pharmaceuticals, Inc. (RYTM) key facts

Strength: Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
Rhythm Pharmaceuticals, Inc. (RYTM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RYTM traded at $86.17, a market capitalization of $6.1 billion.
Return on equity was −251.1% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 15.89 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.